Vis enkel innførsel

dc.contributor.authorHetemäki, Iivo
dc.contributor.authorHeikkilä, Nelli
dc.contributor.authorPeterson, Pärt
dc.contributor.authorKekäläinen, Eliisa
dc.contributor.authorWillcox, Nick
dc.contributor.authorWolff, Anette Susanne Bøe
dc.contributor.authorJarva, Hanna
dc.contributor.authorArstila, T Petteri
dc.date.accessioned2024-12-06T13:06:47Z
dc.date.available2024-12-06T13:06:47Z
dc.date.created2024-08-19T09:59:16Z
dc.date.issued2024
dc.identifier.issn0903-4641
dc.identifier.urihttps://hdl.handle.net/11250/3168719
dc.description.abstractAutoimmune polyendocrinopathy-candidiasis-ectodermal dystrophy (APECED) is an inborn error of immunity affecting both multiple endocrine organs and susceptibility to candidiasis, each with an autoimmune basis. Recently, high titer neutralizing anti-type I interferon (IFN) autoantibodies have been linked with increased severity of SARS-CoV-2 and varicella zoster virus infections in APECED patients. Examining immunity against cytomegalovirus (CMV), we found a higher prevalence of anti-CMV IgG antibodies in patients with APECED (N = 19) than in 44 healthy controls (90% vs 64%, p = 0.04); the similar difference in their IgG levels did not achieve significance (95 ± 74 vs 64 ± 35 IU/mL, ns.). In contrast, the frequency of CMV-specific T cells was lower (804 ± 718/million vs 1591 ± 972/million PBMC p = 0.03). We saw no correlations between levels of anti-CMV IgG and anti-IFN antibodies in APECED patients or in a separate cohort of patients with thymoma (n = 70), over 60% of whom also had anti-IFN antibodies. Our results suggest a dysregulated response to CMV in APECED patients and highlight immunodeficiency to viral infections as part of the disease spectrum.en_US
dc.language.isoengen_US
dc.publisherWileyen_US
dc.rightsNavngivelse 4.0 Internasjonal*
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/deed.no*
dc.titleDecreased T-cell response against latent cytomegalovirus infection does not correlate with anti-IFN autoantibodies in patients with APECEDen_US
dc.typeJournal articleen_US
dc.typePeer revieweden_US
dc.description.versionpublishedVersionen_US
dc.rights.holderCopyright 2024 The Author(s)en_US
cristin.ispublishedtrue
cristin.fulltextoriginal
cristin.qualitycode1
dc.identifier.doi10.1111/apm.13458
dc.identifier.cristin2287341
dc.source.journalAPMIS - Journal of Pathologiy, Microbiology and Immunologyen_US
dc.source.pagenumber881-887en_US
dc.identifier.citationAPMIS - Journal of Pathologiy, Microbiology and Immunology. 2024, 132 (11), 881-887.en_US
dc.source.volume132en_US
dc.source.issue11en_US


Tilhørende fil(er)

Thumbnail

Denne innførselen finnes i følgende samling(er)

Vis enkel innførsel

Navngivelse 4.0 Internasjonal
Med mindre annet er angitt, så er denne innførselen lisensiert som Navngivelse 4.0 Internasjonal